Tertiary Hyperparathyroidism: When Kidney Transplant Does Not Fix the Glands
Written by John P. Sabra, MD FACS
Updated September 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Tertiary hyperparathyroidism is a specific situation that develops after long-standing secondary hyperparathyroidism. It shows up most often in patients who lived with chronic kidney disease for years and then received a kidney transplant. The parathyroid glands, after years of being driven hard, become autonomous. They stop responding to the normal feedback signals even after the underlying problem has been corrected.
The path to tertiary disease starts with secondary hyperparathyroidism. In chronic kidney disease, the kidneys cannot activate vitamin D efficiently. Calcium absorption from the intestines drops, and blood calcium tends to fall. The parathyroid glands respond exactly as they should, by producing more PTH, which at first keeps calcium in the normal range. Over months and years, though, the chronically stimulated glands enlarge. Eventually they develop autonomous function: they keep producing excess PTH regardless of the calcium level.
When a patient like this receives a kidney transplant, the original driver resolves. Vitamin D activation returns to normal. Calcium absorption improves. But the glands, now autonomous, keep producing excess PTH. The result is high calcium, high PTH, and a clinical picture that looks like primary hyperparathyroidism, except it occurs in a patient with a specific renal disease history.
How Tertiary Disease Differs from Primary and Secondary
| Type | Calcium | PTH | Clinical Setting |
|---|---|---|---|
| Primary | High | High or inappropriately normal | Sporadic or syndromic. Normal kidney function. |
| Secondary | Low or normal | High | Chronic kidney disease, vitamin D deficiency, calcium malabsorption. |
| Tertiary | High | High | After kidney transplant or in long-standing CKD with autonomous gland function. |
⚕ Clinical note Roughly 25 to 50% of kidney transplant recipients have persistent hyperparathyroidism in the first year after transplant. Most of these cases resolve on their own as the glands adapt back toward normal function over 6 to 12 months. The patients whose disease persists beyond 12 months are the ones with tertiary hyperparathyroidism, and that group typically needs surgery.
When Surgery Is Indicated
-
Persistent hypercalcemia beyond 12 months after transplant: This is the primary indication. It points to autonomous gland function.
-
Severe hypercalcemia at any time: Even within the first year, severe disease may justify earlier intervention.
-
Bone disease or fractures: Continued parathyroid bone effects despite normal kidney function.
-
Allograft dysfunction: High calcium and PTH can damage the transplanted kidney over time, which is exactly what you want to avoid.
-
Kidney stones: A traditional surgical indication that applies here.
-
Symptoms attributable to hyperparathyroidism: Fatigue, brain fog, and similar symptoms after transplant.
Surgical Approach
The surgical approach to tertiary hyperparathyroidism is similar to surgery for secondary disease in dialysis patients. That usually means subtotal parathyroidectomy, removing 3.5 glands, or total parathyroidectomy with autotransplantation. The choice depends on the surgeon, the patient’s overall situation, and the specific anatomic findings.
Some patients with tertiary disease have a dominant single gland that has become more autonomous than the others. In those cases, more limited surgery may be reasonable. The pattern of disease is worked out from imaging and intraoperative findings, with intraoperative PTH monitoring confirming that enough tissue has been removed.
⚕ Clinical note Tertiary hyperparathyroidism is best managed by a team, with the transplant nephrologist and an endocrine surgeon who works specifically with renal hyperparathyroidism. Ask your surgeon how often they handle this population. The risk of hungry bone syndrome after surgery in these patients is meaningfully higher than in primary hyperparathyroidism, and it requires careful post-operative management.
Cinacalcet as a Bridge
Cinacalcet (Sensipar) is a medication that activates the calcium-sensing receptor on parathyroid cells, which lowers PTH secretion. In tertiary hyperparathyroidism, it is sometimes used to control calcium and PTH in patients who are not surgical candidates, or while waiting to see whether the disease resolves on its own after transplant. It is not a cure. It works only while the patient is taking it. For patients who clearly need definitive treatment, surgery remains the more effective answer.
The Bottom Line
Tertiary hyperparathyroidism develops after long-standing secondary disease, most commonly after kidney transplant. The diagnosis is made when both calcium and PTH stay elevated despite resolution of the original cause. Surgery is the definitive treatment for persistent disease, typically subtotal or total parathyroidectomy with autotransplantation. Team-based management with transplant nephrology and an experienced endocrine surgeon produces the best outcomes.
If you have persistent high calcium and PTH more than 12 months after a kidney transplant, ask your transplant nephrologist for a referral to an endocrine surgeon experienced with tertiary hyperparathyroidism.
This article is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Individual patient circumstances and clinical judgment determine the appropriate evaluation and management for every patient.
More from the Parathyroid Disease series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →